Acute Exacerbations of Chronic Functional Diarrhea
CONTROL OF ACUTE EXACERBATIONS OF CHRONIC FUNCTIONAL DIARRHEA
More than half of the patients experienced statistically significant control of diarrhea by day 2 of treatment with Motofen. Control of diarrhea was consistently maintained at day 4 of treatment.1
Click below to review the full poster on Motofen data
Motofen is now available in pharmacies nationwide.
Please complete the Sample Request form to receive samples.
Important Safety Information
- INDICATIONS AND USAGE
Motofen® (difenoxin and atropine sulfate tablets) is indicated as adjunctive therapy in the
management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.
Motofen® is contraindicated in patients with diarrhea associated with organisms that penetrate
the intestinal mucosa (toxigenic E. coli, Salmonella species, Shigella) and pseudomembranous
colitis associated with broad spectrum antibiotics.
Motofen® is also contraindicated in children under 2 years of age, in patients with known
hypersensitivity to difenoxin, atropine, or any of the inactive ingredients, and in patients who are
Motofen® is not an innocuous drug and dosage recommendations should be strictly adhered to.
Accidental overdose may result in severe respiratory depression and coma, possibly leading to permanent
brain damage or death.
The use of Motofen® does not preclude the administration of appropriate fluid and electrolyte therapy.
Dehydration, particularly in children, may further influence the variability of response to Motofen®
and may predispose to delayed difenoxin intoxication. Drug-induced inhibition of peristalsis may result
in fluid retention in the colon, and this may further aggravate dehydration and electrolyte imbalance.
Use with caution in patients with ulcerative colitis or liver or kidney disease.
Motofen® may produce drowsiness or dizziness. Use caution when engaging in activities
requiring mental alertness, such as driving or operating dangerous machinery.
Keep out of reach of children.
Please click here for full Prescribing Information
REFERENCES: 1. Data on file, Sebela Pharmaceuticals Inc.
2. Motofen [package insert]. Roswell, GA: Sebela Pharmaceuticals Inc.; March 2017.
3. Lomotil Tablets [package insert]. New York, NY: Pfizer Inc.; 2018.
Lomotil is a registered trademark of Pfizer Inc.
Motofen is a registered trademark of Sebela International Ltd.
© 2018 Sebela Pharmaceuticals Inc. All rights reserved. MOT-200-0618E